IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Overview of Drug Design Based on Structure

[1]Tanvi Singh [2] Dr. Swaroop J. Chatterjee [3]Abhishek Maurya

[1] Research Scholer [2] Head of department S.N College of Pharmacy [3] Research Scholer

[1]Pharmacy

[1]S.N College of Pharmacy, Jaunpur, Uttar Pradesh

Abstract

Drug design based on structure is a new powerful approach in modern drug discovery, which uses three-dimensional structures of biological targets to design and optimize the therapeutic compounds. This methodology involves computational and experimental methods to analyze the interaction of potential drugs with their target macromolecules, such as proteins or nucleic acids. Advances in X-ray crystallography, nuclear magnetic resonance (NMR), and cryo-electron microscopy have greatly improved the resolution of target structures, which has enabled the identification of binding sites and critical molecular interactions. DDBS includes two major strategies: ligand-based and target-based approaches. These strategies allow for the rational design of molecules with enhanced affinity, selectivity, and pharmacokinetic properties. DDBS integrates computational tools like molecular docking, molecular dynamics simulations, and free energy calculations into the drug discovery process to accelerate the speed and reduce the cost of conducting experiments. It has proved instrumental in the discovery of many FDA-approved drugs, giving it a bright chance in solving complex diseases and medical needs.

Keywords: Drug design; Molecular docking; DDBS Drug Design Based on Structure, virtual screening, scoring function

Introduction to Drug Design Based on Structure

Structure-based drug design (DDBS) is a computational approach that uses the 3D structures of biological macromolecules, especially proteins, for designing and optimizing small molecules that can modulate their function. It is an important tool in modern drug discovery, providing a more targeted and rational approach than the traditional high-throughput screening methods. DDBS works upon the core principle to explain the atomic level understanding between a drug candidate and its biological target to achieve molecular interactions, so the drug designing is done to enhance the specificity, affinity, and efficacy.

Since advanced techniques like X-ray crystallography, NMR spectroscopy, or cryo-electron microscopy are being applied and put into practice, now one can easily achieve the structures at a high resolution. Such structural information is essential for determining critical binding sites and the kind of conformational change associated with ligand binding. From here, scientists can utilize computation in the form of molecular docking, molecular dynamics simulations, or virtual screening to predict the interaction of a potential drug candidate with the target.

The DDBS approaches generally fall into two broad categories: ligand-based and target-based designs. A ligand-based design can be defined as designing new molecules based on a known ligand that binds to the target, whereas in a target-based design, molecules are optimized simply based on the structure of the target

itself, such as an enzyme or protein. Often, these strategies are also complemented with various other computational methods in refining the lead compounds to predict the pharmacokinetic properties of the compound, its toxicity, and drug-likeness.

Many drugs in different therapeutic areas have been discovered through the application of DDBS, ranging from anticancer drugs to drugs against infectious diseases and neurological disorders. The process not only accelerates drug discovery but also improves the chances of finding active and safe compounds. As the field continues to evolve, DDBS will play a crucial role in the development of next-generation therapeutics, especially when artificial intelligence and machine learning techniques are being increasingly used.



Work Flow Diagram of Drug Design Based on Structure

Detailed Overview of Drug Design Based on Structure

Structure-Based Drug Design (DDBS) is a sophisticated and rational drug discovery approach that utilizes the detailed knowledge of the three-dimensional structures of biological targets, such as proteins, enzymes, or nucleic acids. This method aims to design and optimize molecules that can specifically bind to the target,

modulating its function to achieve therapeutic effects. Below is a comprehensive exploration of the DDBS process, methodologies, applications, and advancements.

1. DDBS Principles

DDBS depends fundamentally on the principle that knowledge of the atomic structure of a biological macromolecule opens the way to the rational design of drug candidates. Such knowledge is obtained by studying small molecules, known as ligands, interacting with the binding site of a target protein-this is often an active site or regulatory pocket.

Important Concepts:

Normally the three-dimensional structure of a target is determined by experimental procedures such as X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy.

Binding Pocket: The specific region of the target where the drug binds. Understanding its geometry, charge distribution, hydrophobicity, and flexibility is critical for drug design.

Molecular Interactions: Key interactions, such as hydrogen bonding, ionic interactions, van der Waals forces, and hydrophobic effects, are studied to optimize ligand binding.

2. Process of DDBS

a. Target Selection

DDBS process begins with the identification of an appropriate biological target related to a disease of interest. Such a target should be properly validated such that its involvement in disease mechanisms has already been well understood.

b. Structure Determination

Laboratory approaches involved are:

X-ray Crystallography: It helps give high-resolution static structures of proteins.

NMR Spectroscopy: It gives information related to protein dynamics and flexibility.

Cryo-Electron Microscopy (Cryo-EM): It has been useful for large protein complexes and membrane proteins.

Computational modeling, including homology modeling, is applied when experimental structures are not available.

c. Binding Site Identification

The binding sites are identified from experimental data, computational algorithms, or co-crystallization with ligands. The site characteristics, such as size, shape, and residue composition, are evaluated.

d. Virtual Screening

Computational screening of large libraries of compounds is carried out to identify those that may have a potential to bind the target. This includes:

SBVS: It uses the target's structure to obtain complementary compounds.

Ligand-based virtual screening: The known ligands use similarity to identify compounds similar to them.

e. Molecular Docking

Docking algorithms make a prediction of how small molecule fits into the binding site. This includes:

Scoring Functions: It computes the strength and quality of the binding.

Pose prediction: It identifies the conformation of the molecule stable within the binding site.

. Lead Optimization

Hits derived from docking and screening are maximized for:

Enhanced binding avidity.

Increased selectivity at the target.

Improved pharmacokinetic properties in general, such as absorption, distribution, metabolism, excretion.

g. Molecular Dynamics Simulations

These simulations probe the structural stability of the drug-target complex over time, protein flexibility, and environmental effects, such as solvent dynamics.

h. Validation and Refinement

Computational models are validated through biochemical assay experiments and structural studies in vitro. Findings gleaned from these experiments enable further refinement.

3. DDBS Methodologies

De Novo Drug Design: Designing completely new compounds based on the target's structure.

Fragment-Based Drug Design (FBDD): Starting with small molecular fragments that bind weakly to the target and combining them into larger, more potent molecules.

High-Throughput Docking: Screening of millions of compounds for possible binding.

Structure-Guided Optimization: Iterative cycles of changing a lead compound using structural information.

4. Usefulness of DDBS

DDBS has led to the creation of many drugs approved clinically, including:

HIV Protease Inhibitors: Developed using the structure of the HIV protease enzyme that blocks viral replication.

Kinase Inhibitors: Targeting protein kinases in cancer, such as imatinib (Gleevec).

Antiviral Drugs: Neuraminidase inhibitors such as oseltamivir (Tamiflu) for influenza.

5. Advantages of DDBS

Rational Approach: Reduces trial-and-error in drug discovery.

Time and Cost Efficiency: Accelerates the identification of promising candidates.

Improved Success Rate: Focuses on compounds with a higher likelihood of success.

Target Selectivity: Minimizes off-target effects, improving safety profiles.

6. Challenges in DDBS

Structural Limitations: High-resolution structures are not always available.

Protein Flexibility: Many computational methods struggle to capture dynamic conformational changes.

Complex Binding Sites: Some targets lack well-defined binding pockets.

Computational Limitations: Accurate prediction of binding affinity and pharmacokinetics remains challenging.

7. DDBS Advances

Machine Learning and AI: Improving predictability and speeding up virtual screening.

Improved Simulation Methods: Quantum Mechanics and advanced force fields.

Integration with Experimental Data: Combining DDBS with high throughput experimental techniques such as cryo-EM.

8. Future Outlook

The integration of artificial intelligence, high-performance computing, and novel experimental techniques is expected to further enhance the capabilities of DDBS. This promises to tackle complex and undruggable targets, development of personalized medicines, and acceleration of timelines in drug discovery.

DDBS is a paradigm shift in drug discovery and redesigning how new therapeutics are designed and optimized. With access to structural information and computational power, it is a powerful toolkit for the solution of some of the most important medical challenges of our time.

Conclusion

Structure-based drug design (DDBS) presents a revolutionary approach in the discovery of drugs, for it allows for the rationally designed synthesis of medicines based on the three-dimensional structures of biological targets. By integrating experimental structural biology techniques with advanced computational methods, DDBS provides valuable insights into molecular interactions and drives the efficient development of highly selective and potent drugs.

The success of the method in producing clinically approved drugs shows that it has potential in the treatment of complex diseases and unmet medical needs. Despite the problems of protein flexibility, structural limitations, and computational complexities, continuous advancements in techniques such as cryo-electron microscopy, molecular dynamics simulations, and machine learning are overcoming these hurdles, making DDBS more precise and accessible.

Looking forward, DDBS will continue to be a bedrock of modern pharmacology, especially as it converges with emerging technologies like artificial intelligence and big data analytics. Its ability to speed up timelines for discovery, reduce costs, and increase drug efficacy makes DDBS a critical tool in the development of next-generation therapeutics, paving the way for an efficient and personalized approach to medicine.

Reference

1.Tollenaere JP (April 1996). "The role of structure-based ligand design and molecular modelling in drug discovery". Pharmacy World & Science. 18 (2): 56–62. doi:10.1007/BF00579706. PMID 8739258. S2CID 21550508

2.Reynolds CH, Merz KM, Ringe D, eds. (2010). Drug Design: Structure- and Ligand-Based Approaches (1 ed.). Cambridge, UK: Cambridge University Press. ISBN 978-0521887236

3.Guner OF (2000). Pharmacophore Perception, Development, and use in Drug Design. La Jolla, Calif: International University Line. ISBN 978-0-9636817-6-8

4.Sanal MG, Paul K, Kumar S, et al. Artificial intelligence and deep learning: the future of medicine and medical practice. J Assoc Physicians India. 2019;67:71–73. [PubMed] [Google Scholar]

5.Sousa MJ, Pesqueira AM, Lemos C, et al. Decision-making based on big data analytics for people management in healthcare organizations. J Med Syst. 2019;43:290. doi: 10.1007/s10916-019-1419-x. [DOI] [PubMed] [Google Scholar]

6.Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18:463–477. doi: 10.1038/s41573-019-0024-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

7.Mohs RC, Greig NH. Drug discovery and development: role of basic biological research. Alzheimers Dement (N Y) 2017;3:651–657. doi: 10.1016/j.trci.2017.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]

8.Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26:80–93. doi: 10.1016/j.drudis.2020.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]

9.Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24:773–780. doi: 10.1016/j.drudis.2018.11.014. [DOI] [PubMed] [Google Scholar]

10.Chan HCS, Shan H, Dahoun T, et al. Advancing drug discovery via artificial intelligence. Trends Pharmacol Sci. 2019;40:592–604. doi: 10.1016/j.tips.2019.06.004. [DOI] [PubMed] [Google Scholar]

11.Vanommeslaeghe K, Guvench O, MacKerell AD., Jr Molecular mechanics. Curr Pharm Des. 2014;20:3281–3292. doi: 10.2174/13816128113199990600.[DOI] [PMC free article] [PubMed] [Google Scholar]

12. Warren GL, Warren SD (2011). "Chapter 16: Scoring Drug-Receptor Interactions". In Gramatica P, Livingstone DJ, Davis AM (eds.). Drug Design Strategies: Quantitative Approaches. RSC Drug Discovery. Royal Society of Chemistry. pp. 440–457. doi:10.1039/9781849733410-00440. ISBN 978-1849731669.

13.N. Roberts, J. Martin, D. Kinchington, A. Broadhurst, J. Craig, I. Duncan, S. Galpin, B. Handa, J. Kay, A. Krohn, *et al*. Rational design of peptide-based HIV proteinase inhibitorsScience, 248 (1990), pp. 358-361 [CrossRef] [Google Scholar]

14.J. Erickson, D. Neidhart, J. VanDrie, D. Kempf, X. Wang, D. Norbeck, J. Plattner, J. Rittenhouse, M. T uron, N. Wideburg, *et al.* Design, activity and 2.8 Å crystal structure of a C2symmetric inhibitor complexed to HIV-1 protease Science, 249 (1990), pp. 527-533 [Google Scholar] [CrossRef]

15.B.D. Dorsey, R.B. Levin, S.L. McDaniel, J.P. Vacca, J.P. Guare, P.L. Darke, J.A. Zugay, E.A. Emini, W.A. Schleif, J.C. Quintero, *et al.*L-735,524: the design of a potent and orally available hiv protease inhibitor J. Med. Chem., 37 (1994), pp. 3443-3451[Google Scholar]

16.V. Mountain Astex, Structural Genomix, and Syrrx Chem. Biol., 10 (2003), pp. 95-98. [Google Scholar] [PMC free article]

17.D. Zheng, Y. Huang, H. Moseley, R. Xiao, J. Aramini, G. Swapna, G. Montelion Automated protein fold determination using a minimal NMR constraint strategy Protein Sci., 12 (2003), pp. 1232-1246 [View in Scopus] [Google Scholar]

18.N. Oezguen, L. Adamian, Y. Xu, K. Rajarathnam, W. Braun Automated assignment and 3D structure calculations using combinations of 2D homonuclear and 3D heteronuclear NOESY spectra J. Biomol. NMR, 22 (2002), pp. 249-263 [View in Scopus] [Google Scholar]

19.C. Bailey-Kellogg, A. Widge, J. Kelley, M. Berardi, J. Bushweller, B. Donald The NOESY jigsaw: automated protein secondary structure and main-chain assignment from sparse, unassigned NMR data J. Comput. Biol., 7 (2000), pp. 537-558[View at publisher] [Crossref View in Scopus] [Google Scholar]

20.K. Pervushin, R. Riek, G. Wider, K. Wutrich Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anistropy indicates an avenue to NMR structures of very large biological macromolecules in solution Proc. Natl. Acad. Sci. USA, 94 (1997), pp. 12366-12371 [View in Scopus] [Google Scholar]

21. J. Antel Integration of combinatorial chemistry and structure-based drug design Curr. Opin. Drug Discov. Dev., 2 (1999), pp. 224-233[View in Scopus] [Google Scholar]

22.C. Verlinde, W. Hol Structure-based drug design: progress, results and challenges Structure, 2 (1994), pp. 577-587 [PMC free article] [CrossRef]

23. Peter A (2023) Principle and Applications of Structure Based Drug Design. Drug Des. 12:235.

24. Sperandio O., Miteva M., Villoutreix B. Combining ligand- and structure-based methods in drug design projects. *Curr. Comput. Aided Drug Des.* 2008;4:250–258. doi: 10.2174/157340908785747447. [CrossRef] [Google Scholar]

25. Talevi A., Gavernet L., Bruno-Blanch L. Combined virtual screening strategies. *Curr. Comput. Aided Drug Des.* 2009;5:23–37. doi: 10.2174/157340909787580854. [CrossRef] [Google Scholar]

26. Spadaro A., Negri M., Marchais-Oberwinkler S., Bey E., Frotscher M. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17®-hydroxysteroid dehydrogenase type 1 (17®-HSD1) *PLoS ONE*. 2012;7:29252. doi: 10.1371/journal.pone.0029252. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Spyrakis F., Bidon-Chanal A., Barril X., Luque F.J. Protein flexibility and ligand recognition: Challenges for molecular modeling. *Curr. Top. Med. Chem.* 2011;11:192–210. doi: 10.2174/156802611794863571. [PubMed] [CrossRef] [Google Scholar]

28. Lexa K.W., Carlson H.A. Protein flexibility in docking and surface mapping. *Q. Rev. Biophys.* 2012;45:301–343. doi: 10.1017/S0033583512000066. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Salmaso V., Moro S. Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. *Front. Pharmacol.* 2018;9:923. doi: 10.3389/fphar.2018.00923. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Chen Y.C. Beware of docking! *Trends Pharmacol. Sci.* 2015;36:78–95. doi: 10.1016/j.tips.2014.12.001. [PubMed]

31.Batool M, Ahmad B, Choi S. (2019). A Structure-Based Drug Discovery Paradigm. *Int J Mol Sci.* 20(11):2783. doi:10.3390/ijms20112783

32.Alderson, T. R. & Kay, L. E. NMR spectroscopy captures the essential role of dynamics in regulating biomolecular function. *Cell* **184,** 577–595 (2021)

33.Berman HM; Westbrook J; Feng Z; Gilliland G; Bhat TN; Weissig H; Shindyalov IN; Bourne PE, The Protein Data Bank. *Nucleic Acids Research* 2000, 28 (1), 235–242. [PMC free article] [PubMed] [Google Scholar]

34.Authier A (2013) Early days of X-ray crystallography, Oxford

35.Bragg WL (1949) The Crystalline state: a general survey, London

36.Cheetham AK, Goodwin AL (2014) Crystallography with powders. Nat Mat 13:760Article Google Scholar

37.Cheung EY, Kitchin SJ, Harris KDM, Imai Y, Tajima N, Kuroda R (2003) Direct structure determination of a multicomponent molecular crystal prepared by a solid-state grinding procedure. J Am Chem Soc 125:14658

Article Google Scholar

38. Tivol WF, Briegel A, Jensen GJ (October 2008). "An improved cryogen for plunge freezing". Microscopy and Microanalysis. **14** (5): 375–379. Bibcode:2008MiMic..14..375T. doi:10.1017/S1431927608080781. PMC 3058946. PMID 18793481.

39.Cheng Y, Grigorieff N, Penczek PA, Walz T (April 2015). "A primer to single-particle cryo-electron microscopy". Cell. **161** (3): 438–449. doi:10.1016/j.cell.2015.03.050. PMC 4409659. PMID 25910204.

40.Stoddart C (1 March 2022). "Structural biology: How proteins got their close-up". Knowable Magazine. doi:10.1146/knowable-022822-1. S2CID 247206999. Retrieved 25 March 2022

41.Herzik, Mark A.; Wu, Mengyu; Lander, Gabriel C. (2019-03-04). "High-resolution structure determination of sub-100 kDa complexes using conventional cryo-EM". Nature Communications. **10** (1): 1032. Bibcode:2019NatCo..10.1032H. doi:10.1038/s41467-019-08991-8. ISSN 2041-1723. PMC 6399227. PMID 30833564.

42.Castells-Graells R, Meador K, Arbing MA, Sawaya MR, Gee M, Cascio D, et al. (September 2023). "Cryo-EM structure determination of small therapeutic protein targets at 3 Å-resolution using a rigid imaging scaffold". Proceedings of the National Academy of Sciences of the United States of America. **120** (37): e2305494120. Bibcode:2023PNAS..12005494C. doi:10.1073/pnas.2305494120. PMC 10500258. PMID 37669364.

43.Schlick T (1996). "Pursuing Laplace's Vision on Modern Computers". Mathematical Approaches to Biomolecular Structure and Dynamics. The IMA Volumes in Mathematics and its Applications. Vol. 82. pp. 219–247. doi:10.1007/978-1-4612-4066-2_13. ISBN 978-0-387-94838-6.

44. Ferraro M; D'Annessa I; Moroni E; Morra G; Paladino A; Rinaldi S; Compostella F; Colombo G, Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design. *Journal of medicinal chemistry* 2019, 62 (1), 60–87. [PubMed] [Google Scholar]

45.B Mukesh, K Rakesh. Molecular docking: a review. IJRAP. 2011; 2: 1746-1751.

46.IA Guedes, CS de Magalhães, LE Dardenne. Receptor–ligand molecular docking, Biophysical Reviews. 2014; 6: 75-87.